First Guideline on Cardiovascular-Kidney-Metabolic Syndrome Released
The first dedicated U.S. guideline for cardiovascular-kidney-metabolic (CKM) syndrome makes a big push to unite primary and specialty care in managing large swaths of the population. The American Heart Association (AHA) and the American College of Cardiology (ACC) now stress interdisciplinary collaboration among cardiologists, endocrinologists, nephrologists, and primary care clinicians caring for patients at various […]
CDC Trust Falls Sharply; Watchdog Flags Medicaid Gaps; Drug Targets ‘Ozempic Butt’
Resumen de Confianza en CDC Only 50% of the public said they now trust health recommendations from the CDC, down from 77% in spring 2025. This finding comes from a poll by the Harvard School of Public Health and the de Beaumont Foundation’s Public Health Listening Lab. Informe sobre Medicaid El HHS Office of Inspector […]
First-trimester GLP-1 exposure not tied to higher risk of adverse pregnancy outcomes
Clinical Takeaway: Unintentional early pregnancy exposure to GLP-1 receptor agonists may be less concerning than previously feared. Although these data don’t establish safety, they may help inform counseling when pregnancy occurs before a GLP-1 can be discontinued. GLP-1 receptor agonist use has increased rapidly among women of reproductive age for both type 2 diabetes and […]
FDA Issues Safety Alert on Weight-Loss Drug’s Kidney Risks
FDA Updates Orlistat Warnings The FDA issued a drug safety communication approving a label change that warns about the risk of kidney stones or kidney injury with the over-the-counter (OTC) weight loss drug orlistat (Alli), the agency said Wednesday. The label now recommends that consumers with a history of kidney disease or kidney stones consult […]
Lawsuits Claiming Social Media Is ‘Addictive’ Gain Momentum
Social media has been on trial for allegedly harming youth mental health, and tech companies have been facing uphill legal battles in recent months. In a landmark case in March, a California jury found Meta and Google liable for the depression and anxiety of a woman who compulsively used social media as a child, awarding […]
Trial: Vitamin K Supplement Curbs Coronary Atherosclerosis
Menaquinone-7 (MK-7) supplementation modestly slowed the progression of coronary artery calcification (CAC) for patients in the placebo-controlled VitaK-CAC trial. Among people with existing chronic coronary atherosclerosis, CT-derived CAC scores rose to varying degrees between people randomized to the vitamin K homologue or matching placebo, going from 135 AU and 145 AU at baseline, respectively, to […]
Rabbit Fever Alert; Med School Faces Bias Claim; TAVR Program Still Under Fire
Alert sobre fiebre del conejo Health officials sounded the alarm on the presence of tularemia, or “rabbit fever,” in northern Colorado. (USA Today via Yahoo!) Aumento de casos de Ébola en Congo The number of confirmed Ebola cases in Congo rose to 635, including 127 deaths. (Reuters via MSN) Iniciativa de concienciación sobre Ébola In […]
Adjuvant Combination for Kidney Cancer Gets FDA’s Blessing
The FDA on Friday approved belzutifanopens in a new tab or window (Welireg) plus pembrolizumab (Keytruda, Keytruda Qlex) as adjuvant therapy for renal cell carcinoma (RCC) with a clear cell component. Based on results from LITESPARK-022opens in a new tab or window, the combination is indicated for adults at intermediate-high or high risk of recurrence […]
Eminent Psychiatrist Dies; Editing Embryo DNA; Acetaminophen vs Ibuprofen
Harvard Professor Passes Away Harvard University professor Robert Coles, MD, the psychiatrist and Pulitzer Prize-winning author who championed the cause of children grappling with poverty and segregation, died at age 97. (AP) New World Screwworm Infection Detected A second case of New World screwworm infection has been detected in a Texas calf, the U.S. Department […]
Talquetamab Regimens Boost Survival in Multiple Myeloma
Talquetamab (Talvey) plus daratumumab (Darzalex) with or without pomalidomide (Pomalyst) significantly improved survival outcomes over an active regimen for relapsed or refractory multiple myeloma, a phase III trial showed. Among patients who had previously received at least one line of therapy, estimated 24-month progression-free survival (PFS) rates reached 81.3% with talquetamab plus daratumumab and pomalidomide […]